Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
Phase 1
- Conditions
- Non Muscle Invasive Bladder Cancer
- Interventions
- Biological: Ty21a
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- Patrice Jichlinski
- Target Recruit Count
- 25
- Registration Number
- NCT03421236
- Locations
- 🇨ðŸ‡
Dpt Urology- CHUV, Lausanne, Vaud, Switzerland
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
Phase 1
Completed
- Conditions
- Bladder Cancer
- Interventions
- Biological: MAGE-A3 ASCIBiological: BCG
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Patrice Jichlinski
- Target Recruit Count
- 23
- Registration Number
- NCT01498172
- Locations
- 🇨ðŸ‡
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
© Copyright 2025. All Rights Reserved by MedPath